Haemoglobin levels and health-related quality of life in young and elderly patients on specialized predialysis care

Nephrology Dialysis Transplantation

Volumn 29, Issue 7, 2014, Pages 1391-1398

  De Goeij, Moniek C M ^a   Meuleman, Yvette ^a   Van Dijk, Sandra ^a   Grootendorst, Diana C ^a,b   Dekker, Friedo W ^a   Halbesma, Nynke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

anaemia medication; elderly; haemoglobin; health related quality of life; predialysis care

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; ELDERLY CARE; EMOTIONALITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MENTAL HEALTH; OUTCOME ASSESSMENT; PHYSICAL CAPACITY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; SPECIALIZED PREDIALYSIS CARE;

ANAEMIA MEDICATION; ELDERLY; HAEMOGLOBIN; HEALTH-RELATED QUALITY OF LIFE; PREDIALYSIS CARE;

AGE FACTORS; AGED; ANEMIA; BIOLOGICAL MARKERS; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMOGLOBINS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RENAL DIALYSIS;

EID: 84903837988     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft533     Document Type: Article

References (42)

1. Astor BC, Muntner P, Levin A et al. Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002.; 162: 1401-1408
2. Farag YM, Keithi-Reddy SR, Mittal BV et al. Anemia, inflammation and health-related quality of life in chronic kidney disease patients. Clin Nephrol 2011.; 75: 524-533
3. Finkelstein FO, Story K, Firanek C et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009.; 4: 33-38
4. Holland DC, Lam M. Predictors of hospitalization and death among predialysis patients: A retrospective cohort study. Nephrol Dial Transplant 2000.; 15: 650-658
5. Keane WF, Brenner BM, de Zeeuw D et al. The risk of developing endstage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int 2003.; 63: 1499-1507
6. Levin A, Djurdjev O, Duncan J et al. Haemoglobin at time of referral prior to dialysis predicts survival: An association of haemoglobin with long-term outcomes. Nephrol Dial Transplant 2006.; 21: 370-377
7. Li S, Foley RN, Collins AJ. Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease. Int Urol Nephrol 2005.; 37: 395-402
8. Vlagopoulos PT, Tighiouart H, Weiner DE et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: The impact of chronic kidney disease. J Am Soc Nephrol 2005.; 16: 3403-3410
9. Voormolen N, Grootendorst DC, Urlings TA et al. Prevalence of anemia and its impact on mortality and hospitalization rate in predialysis patients. Nephron Clin Pract 2010.; 115: C133Yc141
10. Fink J, Blahut S, Reddy M et al. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001.; 37: 348-355
11. Jones M, Ibels L, Schenkel B et al. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: A meta-Analysis. Kidney Int 2004.; 65: 757-767
12. Jungers P, Choukroun G, Oualim Z et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001.; 16: 307-312
13. Provenzano R, Garcia-Mayol L, Suchinda P et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 2004.; 61: 392-405
14. Ross SD, Fahrbach K, Frame D et al. The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review. Clin Ther 2003.; 25: 1786-1805
15. Clement FM, Klarenbach S, Tonelli M et al. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: A systematic review and meta-Analysis. Arch Intern Med 2009.; 169: 1104-1112
16. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992.; 30: 473-483
17. Knight EL, Ofsthun N, Teng M et al. The association between mental health, physical function, and hemodialysis mortality. Kidney Int 2003.; 63: 1843-1851
18. Lowrie EG, Curtin RB, LePain N et al. Medical outcomes study short form-36: A consistent and powerful predictor of morbidity and mortality in dialysis patients. Am J Kidney Dis 2003.; 41: 1286-1292
19. Palmer SC, Navaneethan SD, Craig JC et al. Meta-Analysis: Erythropoiesisstimulating agents in patients with chronic kidney disease. Ann Intern Med 2010.; 153: 23-33
20. Aaronson NK, Muller M, Cohen PD et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998.; 51: 1055-1068
21. Chin HJ, Song YR, Lee JJ et al. Moderately decreased renal function negatively affects the health-related quality of life among the elderly Korean population: A population-based study. Nephrol Dial Transplant 2008.; 23: 2810-2817
22. Dutch Federation of Nephrology. Multidisciplinary Guidelines Predialysis. Dutch Federation of Nephrology 2011. http://www.nefro.nl/ uploads/4W/qX/ 4WqXEPuAQTj88b4CjAj-2g/multidisciplinaire-richtlijn- predialyse-webversie- 20110401.pdf (10 January 2014, date last accessed)
23. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002.; 39: S1-266
24. Kidney Disease: Improving Global Outcomes (KDIGO). Clinical Practice Guidelines. KDIGO 2011
25. European Renal Association/Dialysis and Transplantation Association (ERA/EDTA) Registry. Annual report 2009. ERA/EDTA Registry 2009
26. Levey AS, Greene T, Kusek JW et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000.; 11:155A
27. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. 2007 update of hemoglobin target. Am J Kidney Dis 2007.; 50: 471-530
28. Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int 2009.; 75: 15-24
29. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999.; 18: 681-694
30. Donders AR, van der Heijden GJ, Stijnen T et al. Review: A gentle introduction to imputation of missing values. J Clin Epidemiol 2006.; 59: 1087-1091
31. Moons KG, Donders RA, Stijnen T, Jr. et al. Using the outcome for imputation of missing predictor values was preferred. J Clin Epidemiol 2006.; 59: 1092-1101
32. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006.; 355: 2071-2084
33. Levin A, Djurdjev O, Thompson C et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005.; 46: 799-811
34. Ritz E, Laville M, Bilous RW et al. Target level for hemoglobin correction in patients with diabetes and CKD: Primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007.; 49: 194-207
35. Roger SD, McMahon LP, Clarkson A et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial. J Am Soc Nephrol 2004.; 15: 148-156
36. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006.; 355: 2085-2098
37. Macdougall IC. Individualizing target haemoglobin concentrations - tailoring treatment for renal anaemia. Nephrol Dial Transplant 2001.; 16 (Suppl 7): 9-14
38. Bamgbola OF. Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease. Kidney Int 2011.; 80: 464-474
39. Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. J Clin Epidemiol 2001.; 54 (Suppl 1): S57YS60
40. Muntner P, Judd SE, Krousel-Wood M et al. Low medication adherence and hypertension control among adults with CKD: Data from the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. Am J Kidney Dis 2010.; 56: 447-457
41. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: Meta-Analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000.; 160: 2101-2107
42. Holt EW, Muntner P, Joyce CJ et al. Health-related quality of life and antihypertensive medication adherence among older adults. Age Ageing 2010.; 39: 481-487